BACKGROUND/AIM: The coronavirus disease 2019 (COVID-19) pandemic prompted global recommendations to delay non-urgent endoscopic procedures to limit the spread of SARS-COV-2, but such delays had unprecedented impact on the delivery of healthcare. Being a large specialty GI Pathology service, we sought to analyze the effect of the pandemic on the frequency of GI malignancies in our department. PATIENTS AND METHODS: Based on the electronic search of departmental pathology records, we compared the total numbers of cancer diagnoses (primary and metastatic) from various GI biopsy sites during the 12-month pre- and post-pandemic periods. We summarized patient demographics and analyzed pertinent histopathologic data. RESULTS: For all GI biopsy sites, the number of intramucosal/invasive malignancies reported during the one-year pre-COVID-19 pandemic (pre-COVID) and post-COVID-19 pandemic national lockdown (post-COVID) observation periods were 146 and 218, respectively. Among these, 32 and 70 malignancies were reported for the first quarter (representing the earliest post-lockdown period), 29 and 53 for the second, 41 and 54 for the third, and 44 and 41 for the fourth quarter. During the first two quarters of the post-COVID observation period, the increase in malignant diagnoses was most profound, showing 119% post-COVID increase compared to the pre-COVID levels. Of the two main primary histologic types of large intestinal carcinomas [adenocarcinoma (ADC) and squamous cell carcinoma (SCC)], the most profound post-COVID increase was noted in SCCs (136% vs. 58% for ADCs). CONCLUSION: Compared to the pre-pandemic baseline, the COVID-19 pandemic caused a major increase in biopsy diagnoses of GI cancers in our department. The most plausible explanations for this trend include inevitable lockdowns to minimize the spread of SAR-COV2, which affected GI endoscopy procedure schedules/re-schedules as well as patient response and adaptation to emerging post-COVID GI healthcare patterns. The COVID-19 pandemic's long-term impact on the health of GI cancer patients will need to be determined through systematic analyses by multi-disciplinary teams. Copyright 2022, International Institute of Anticancer Research.
BACKGROUND/AIM: The coronavirus disease 2019 (COVID-19) pandemic prompted global recommendations to delay non-urgent endoscopic procedures to limit the spread of SARS-COV-2, but such delays had unprecedented impact on the delivery of healthcare. Being a large specialty GI Pathology service, we sought to analyze the effect of the pandemic on the frequency of GI malignancies in our department. PATIENTS AND METHODS: Based on the electronic search of departmental pathology records, we compared the total numbers of cancer diagnoses (primary and metastatic) from various GI biopsy sites during the 12-month pre- and post-pandemic periods. We summarized patient demographics and analyzed pertinent histopathologic data. RESULTS: For all GI biopsy sites, the number of intramucosal/invasive malignancies reported during the one-year pre-COVID-19 pandemic (pre-COVID) and post-COVID-19 pandemic national lockdown (post-COVID) observation periods were 146 and 218, respectively. Among these, 32 and 70 malignancies were reported for the first quarter (representing the earliest post-lockdown period), 29 and 53 for the second, 41 and 54 for the third, and 44 and 41 for the fourth quarter. During the first two quarters of the post-COVID observation period, the increase in malignant diagnoses was most profound, showing 119% post-COVID increase compared to the pre-COVID levels. Of the two main primary histologic types of large intestinal carcinomas [adenocarcinoma (ADC) and squamous cell carcinoma (SCC)], the most profound post-COVID increase was noted in SCCs (136% vs. 58% for ADCs). CONCLUSION: Compared to the pre-pandemic baseline, the COVID-19 pandemic caused a major increase in biopsy diagnoses of GI cancers in our department. The most plausible explanations for this trend include inevitable lockdowns to minimize the spread of SAR-COV2, which affected GI endoscopy procedure schedules/re-schedules as well as patient response and adaptation to emerging post-COVID GI healthcare patterns. The COVID-19 pandemic's long-term impact on the health of GI cancer patients will need to be determined through systematic analyses by multi-disciplinary teams. Copyright 2022, International Institute of Anticancer Research.
Entities:
Keywords:
COVID-19 pandemic; GI endoscopy; Gastrointestinal cancer; diagnosis; gastroenterology; impact
Authors: M Elisabeth Del Giudice; Emily T Vella; Amanda Hey; Marko Simunovic; William Harris; Cheryl Levitt Journal: Can Fam Physician Date: 2014-08 Impact factor: 3.275
Authors: Sophie Balzora; Rachel B Issaka; Adjoa Anyane-Yeboa; Darrell M Gray; Folasade P May Journal: Gastrointest Endosc Date: 2020-06-20 Impact factor: 9.427
Authors: Hanqing Liu; Ling Zhan; Liantao Guo; Xizi Yu; Lingrui Li; Hongfang Feng; Dan Yang; Zhiliang Xu; Yi Tu; Chuang Chen; Shengrong Sun Journal: Int J Gen Med Date: 2021-10-27
Authors: Evan Williams; Joseph C Kong; Parry Singh; Swetha Prabhakaran; Satish K Warrier; Stephen Bell Journal: ANZ J Surg Date: 2021-07-16 Impact factor: 1.872
Authors: Neil S Zheng; Jeremy L Warner; Travis J Osterman; Quinn S Wells; Xiao-Ou Shu; Stephen A Deppen; Seth J Karp; Shon Dwyer; QiPing Feng; Nancy J Cox; Josh F Peterson; C Michael Stein; Dan M Roden; Kevin B Johnson; Wei-Qi Wei Journal: J Biomed Inform Date: 2020-12-10 Impact factor: 8.000
Authors: Alvina G Lai; Laura Pasea; Amitava Banerjee; Geoff Hall; Spiros Denaxas; Wai Hoong Chang; Michail Katsoulis; Bryan Williams; Deenan Pillay; Mahdad Noursadeghi; David Linch; Derralynn Hughes; Martin D Forster; Clare Turnbull; Natalie K Fitzpatrick; Kathryn Boyd; Graham R Foster; Tariq Enver; Vahe Nafilyan; Ben Humberstone; Richard D Neal; Matt Cooper; Monica Jones; Kathy Pritchard-Jones; Richard Sullivan; Charlie Davie; Mark Lawler; Harry Hemingway Journal: BMJ Open Date: 2020-11-17 Impact factor: 2.692